Dr.Reddy's Laboratories Ltd (RDY.N)
21 Feb 2017
Tue, Feb 21 2017
* Says the audit of API manufacturing plant at Miryalaguda, by the US FDA, has been completed on February 21, 2017
* Clarifies on news item "Dr. Reddy's announces US district court's opinion relating to patent infringement"
* Says Dr. Reddy's Laboratories announces U.S. district court's opinion relating to patent infringement
* Dr.Reddy's Laboratories clarifies on news item "Korean biotech firm Mezzion Pharma files suit against Dr Reddy's laboratories."
* Clarifies on news item "FDA to re-audit three Dr.Reddy's labs plants"
* Announces the launch of Raloxifene HCI tablets, USP in the U.S. Market Source text: http://bit.ly/2fHr5V4 Further company coverage:
* Sucampo pharmaceuticals inc - company raises 2016 guidance and provides preliminary 2017 guidance
* Exec says have addressed all FDA requirements on warning letters
* Co to continue to focus on launching new products in generic business
* Dr. Reddy's Laboratories announces the launch of Aripiprazole tablets, USP tablets in the U.S. market Source text for Eikon: Further company coverage: (Bengaluru newsroom)